A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C.
10.3350/kjhep.2009.15.4.496
- Author:
Mi Na KIM
1
;
Ki Tae YOON
;
Jun Yong PARK
;
Do Young KIM
;
Sang Hoon AHN
;
Chae Yoon CHON
;
Kwang Hyub HAN
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. gihankhys@yuhs.ac
- Publication Type:Original Article ; Comparative Study ; English Abstract
- Keywords:
Chronic hepatitis C;
Genotype 1;
Peginterferon;
Ribavirin
- MeSH:
Adult;
Age Factors;
Aged;
Antiviral Agents/*administration & dosage/therapeutic use;
Drug Administration Schedule;
Drug Therapy, Combination;
Female;
Genotype;
Hepacivirus/genetics;
Hepatitis C, Chronic/*drug therapy;
Humans;
Interferon Alfa-2a/*administration & dosage/therapeutic use;
Male;
Middle Aged;
Multivariate Analysis;
Polyethylene Glycols/*administration & dosage/therapeutic use;
RNA, Viral/blood;
Ribavirin/*administration & dosage/therapeutic use
- From:The Korean Journal of Hepatology
2009;15(4):496-503
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The standard therapy for patients with genotype 1 chronic hepatitis C (CHC) is a combination of peginterferon and ribavirin for 48 weeks. However, the most appropriate duration of treatment remains to be established because of treatment-related side effects and cost. The aim of this study was to compare the efficacies of 24- and 48-week treatments, and to assess the efficacy of split 24-week therapy (a further 24 weeks of treatment in patients with relapse after the initial 24 weeks of treatment). METHODS: A total of 130 patients with genotype 1 CHC was treated between June 2004 and December 2006. Patients with undetectable HCV RNA at 24 weeks of treatment (as assessed by qualitative PCR assay; n=101 patients) were allowed to choose either 24 or 48 weeks as the duration of their treatment; 51 patients chose the 24-week treatment regimen and the remainder chose the 48-week regimen. Patients who relapsed after 24 weeks of treatment were treated for further 24 weeks. The sustained virologic response (SVR) of each treatment group was analyzed. RESULTS: The SVR rate was higher in patients treated for 48 weeks than in those treated for 24 weeks (74.0% vs. 52.9%, P=0.028). In the multivariate analysis, age < 50 years, platelets > or = 150,000/mm3, and treatment duration for 48 weeks remained significant independent predictors of SVR. Fourteen of the 24 patients who relapsed in the 24-week treatment group received split 24-week therapy, and 6 patients (42.9%) achieved SVR. The overall SVR rate did not differ significantly between the 24-week treatment group, including those who underwent 24-week split therapy (64.7%), and the 48-week treatment group (64.7% vs. 74%, P=0.311). CONCLUSIONS: The 24-week plus additional split 24-week therapy following failure is a useful treatment strategy for patients with genotype 1 CHC.
